|
|
|
Volumn , Issue MAY, 2003, Pages 29-33
|
|
Unlocking the value of failed CNS trials
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
CARDIOVASCULAR AGENT;
CENTRAL NERVOUS SYSTEM AGENTS;
CYCLOBENZAPRINE;
GENERIC DRUG;
PLACEBO;
TOFISOPAM;
ANXIETY NEUROSIS;
ARTICLE;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL TRIAL;
COMPETITION;
DECISION MAKING;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
ECONOMIC ASPECT;
FIBROMYALGIA;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PATENT;
PATIENT CARE;
PROBLEM SOLVING;
RISK ASSESSMENT;
SIDE EFFECT;
SOCIAL PSYCHOLOGY;
TREATMENT FAILURE;
|
|
EID: 0038413679
PISSN: 14727463
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
